Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
6.84
-0.26 (-3.66%)
At close: Jul 11, 2025, 4:00 PM
6.85
+0.01 (0.15%)
After-hours: Jul 11, 2025, 7:50 PM EDT
Novavax Revenue
Novavax had revenue of $666.66M in the quarter ending March 31, 2025, with 610.30% growth. This brings the company's revenue in the last twelve months to $1.25B, up 25.92% year-over-year. In the year 2024, Novavax had annual revenue of $682.16M, down -30.65%.
Revenue (ttm)
$1.25B
Revenue Growth
+25.92%
P/S Ratio
0.86
Revenue / Employee
$1,318,237
Employees
952
Market Cap
1.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 682.16M | -301.54M | -30.65% |
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
NVAX News
- 4 weeks ago - Novavax, Inc. (NVAX) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Novavax's COVID-flu combo and standalone flu shots improve immunity in late-stage study - Reuters
- 4 weeks ago - Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial - PRNewsWire
- 4 weeks ago - Vaccine actions and policy positions under US Health Secretary Kennedy - Reuters
- 4 weeks ago - Vaccine stocks muted as Wall Street takes 'wait and watch' approach after Kennedy's shake-up - Reuters
- 4 weeks ago - Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. - Barrons
- 6 weeks ago - Novavax to Participate in Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - Novavax: Nuvaxovid FDA Approval Unlocks Several Bullish Stimuli - Seeking Alpha